This listing of claims will replace all prior versions and listings of claims in the application:

1-16. (Canceled)

17. (Currently amended) A method of inhibiting the expression of CD40 in a cell or tissue comprising contacting said cell or tissue with an antisense compound 8 to 80 nucleobases in length targeted to a nucleic acid molecule encoding CD40, wherein said compound is at least 70% complementary to said nucleic acid molecule encoding CD40, and wherein said compound inhibits the expression of CD40 mRNA by at least 10% ~~the antisense compound of claim 1 so that expression of CD40 is inhibited~~.

18. (Original) The method of claim 17 wherein said cells are B-cells or macrophages.

19-22. (Canceled)

23. (Currently amended) A method of treating an animal having a disease or condition associated with CD40 comprising administering to said animal a therapeutically or prophylactically effective amount of an antisense compound 8 to 80 nucleobases in length targeted to a nucleic acid molecule encoding CD40, wherein said compound is at least 70% complementary to said nucleic acid molecule encoding CD40, and wherein said compound inhibits the expression of CD40 mRNA by at least 10% ~~the antisense compound of claim 1 so that expression of CD40 is inhibited~~.

24. (Original) The method of claim 23 wherein the disease or condition is an immune-associated disorder, an inflammatory condition or a hyperproliferative condition.

25. (Original) The method of claim 24 wherein the immune-associated disorder is graft-versus-host disease, allograft rejection or an autoimmune disease or condition.

26. (Original) The method of claim 24 wherein the inflammatory condition is asthma, rheumatoid arthritis, allograft rejection, inflammatory bowel disease or psoriasis.

27. (Original) The method of claim 24 wherein the hyperproliferative condition is atherosclerosis, cancer or a tumor.

28-61. (Canceled)

62. (Currently amended) A method of redirecting splicing of CD40 RNA in a cell or tissue comprising contacting said cell or tissue with an antisense compound of 8 to 80 nucleobases in length targeted to a nucleic acid molecule encoding CD40, wherein said compound is at least 70% complementary to said nucleic acid molecule encoding CD40, and wherein said compound does not elict RNase H cleavage of its RNA target in an antisense compound-target RNA duplex ~~claim 57, so that the ratio of CD40 splice products is altered~~.

63. (Original) The method of claim 62 wherein the ratio of CD40 Type 2 transcript is increased relative to the CD40 Type 1 transcript.

64. (Original) The method of claim 63 wherein CD40 signaling is reduced.

65. (Original) The method of claim 64 wherein IL-12 cytokine production is reduced.

66. (Original) A method of reducing CD40 signaling in a cell or tissue comprising contacting said cell or tissue with an antisense compound of 8 to 80 nucleobases in length targeted to a nucleic acid molecule encoding CD40, wherein said compound is at least 70% complementary to said nucleic acid molecule encoding CD40, and wherein said compound does not elict RNase H cleavage of its RNA target in an antisense compound-target RNA duplex ~~claim 57~~, so that the ratio of CD40 splice products is altered and CD40 signaling is reduced.

67. (Currently amended) A method of reducing IL-12 cytokine production in a cell or tissue comprising contacting said cell or tissue with an antisense compound of 8 to 80 nucleobases in length targeted to a nucleic acid molecule encoding CD40, wherein said compound is at least 70% complementary to said nucleic acid molecule encoding CD40, and wherein said compound does not elict RNase H cleavage of its RNA target in an antisense compound-target RNA duplex ~~claim 57~~, so that the ratio of CD40 splice products is altered and IL-12 cytokine production is reduced.

68-69. (Canceled)